



Proteomics International

LABORATORIES LTD

**ASX Release
23 January 2024**

ASX code: PIQ

Proteomics International receives commitments for A\$6.5m in Institutional Placement

- **Proteomics International has secured binding and irrevocable commitments for A\$6.5 million via an institutional placement**
- **Founder and Managing Director Dr Richard Lipscombe has also agreed to sell down A\$2 million worth of shares to facilitate institutional participation without additional equity dilution**
- **Funds raised from the placement will be used to commercialise the PromarkerD predictive test for diabetic kidney disease and fund further development of the Promarker diagnostics pipeline and general working capital**
- **The placement has been to leading institutional investors in Asia and Australia**

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), a pioneer in predictive diagnostics is pleased to announce that it has received firm commitments from new and existing institutional investors for a non-underwritten placement of 8.6 million new fully paid ordinary shares (“New Shares”) at A\$0.76 per New Share (“Placement Price”) to raise A\$6.5 million in gross proceeds (“Placement”). The issue price of A\$0.76 is at a 11.5% discount to the five-day volume weighted average price and a 16.5% to the last close price as at Monday, 22 January 2024. Jefferies (Australia) Pty Ltd acted as Lead Manager to the Placement.

Proteomics International Managing Director Dr Richard Lipscombe said, *“We are delighted to announce this institutional placement to leading institutional investors in Asia and Australia. These investors have actively researched and engaged with the Company and are investing at a pivotal point ahead of our commercialisation of PromarkerD and further clinical development of our diagnostics pipeline. The support from these institutions will position Proteomics International well to execute on its commercial and development plans.”*

Placement

Details of the Placement are as follows:

- The Placement is being made to new and existing shareholders and comprises the issue of 8.6 million New Shares for gross proceeds of approximately A\$6.5 million
- The New Shares will be issued pursuant to Proteomics International’s placement capacity under ASX Listing Rule 7.1 and is expected to settle on Thursday, 25 January 2024

New Shares issued under the Placement will rank pari passu with existing PIQ fully paid ordinary shares from their date of issue.

Concurrent Secondary Sell-Down

Concurrent with the Placement, Proteomics International Founder and Managing Director Dr Richard Lipscombe has agreed to sell approximately 2.6 million shares, representing 14% of his shareholding in the Company (“Sell-Down”). The Sell-Down will take place at the same price at which New Shares are being issued under the Placement. The Sell-Down reflects the first sale of shares by Dr Lipscombe since the Company’s inception in 2001 and has been conducted in conjunction with the Placement to facilitate institutional investor participation without additional equity dilution.

Use of Proceeds

The Company will use the proceeds received from the Placement for:

- Commercialisation of the PromarkerD predictive test for diabetic kidney disease
- Development of the Promarker diagnostics pipeline
- General working capital purposes

Indicative timetable*

Event	Date
Lodgement of ASX Offer Announcement	Tuesday, 23 January 2024
Settlement of New Securities issued under the Offer	Thursday, 25 January 2024
Allotment (and normal trading) of new Securities issued under the Offer	Monday, 29 January 2024

* All times referenced are to Sydney time, Australia unless denoted otherwise. This timetable is indicative only and PIQ may, at its discretion, vary any of the above dates, subject to the ASX Listing Rules and the *Corporations Act 2001* (Cth) and other applicable laws. The commencement of trading and quotation of New Shares is subject to ASX confirmation.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).

ENDS

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

About PromarkerD (www.PromarkerD.com)

Diabetic kidney disease (DKD) is a serious complication arising from diabetes which if unchecked can lead to dialysis or kidney transplant. PromarkerD is a prognostic test that can predict future kidney function decline in patients with type 2 diabetes and no existing DKD. The patented PromarkerD test system uses a simple blood test to detect a unique ‘fingerprint’ of the early onset of the disease by measuring three serum protein biomarkers, combined with three routinely available conventional clinical variables (age, HDL-cholesterol and estimated glomerular filtration rate (eGFR)). A cloud-based algorithm integrates the results into a patient risk report. In clinical studies published in

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

leading journals PromarkerD correctly predicted up to 86% of otherwise healthy diabetics who went on to develop diabetic kidney disease within four years.

Further information is available through the PromarkerD web portal.

To visit the PromarkerD virtual booth please see: www.PromarkerD.com/product

About the Promarker™ Platform

Proteomics International's diagnostics development is made possible by the Company's proprietary biomarker discovery platform called Promarker, which searches for protein 'fingerprints' in a sample. This disruptive technology can identify proteins that distinguish between people who have a disease and people who do not, using only a simple blood test. It is a powerful alternative to genetic testing. The technology is so versatile it can be used to identify fingerprints from any biological source, from wheat seeds to human serum. The Promarker platform was previously used to develop PromarkerD, a world-first predictive test for diabetic kidney disease, that is currently being commercialised. Other tests in development include for asthma & COPD, oesophageal cancer, diabetic retinopathy and oxidative stress.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Lisa Barnes
Public Relations
Profile Media
T: +61 416 583 672
E: lisab@profilemedia.com.au

Dirk van Dissel
Investor Relations
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au